Gain Therapeutics (NASDAQ: GANX) 2025 loss narrows as cash doubles

NodeGuardian · 2026-03-30T03:16:53+00:00

Gain Therapeutics' 2025 financial results show a narrowed net loss of $20.2 million and increased cash reserves of $20.8 million. Positive Phase 1b data for its Parkinson's candidate GT-02287 sets the stage for anticipated milestones in 2026, including IND clearance and a Phase 2 trial.

NodeGuardian

2026-03-30 03:16:53

Abstract generation in progress

Gain Therapeutics reported its 2025 financial results, showing a narrowed net loss of $20.2 million compared to $20.4 million in 2024, with its cash reserves more than doubling to $20.8 million. The company also provided an update on its lead Parkinson’s disease candidate, GT-02287, highlighting encouraging Phase 1b data with central nervous system target engagement and stable or improved clinical scores. Gain Therapeutics anticipates significant milestones in 2026, including IND clearance for GT-02287 and the initiation of a Phase 2 clinical trial.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes